Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
AbelZeta Inc. clinical trials
Also known as CBMG, Cellular Biomedicine Group.
The registry lists 24 studies whose lead sponsor is AbelZeta Inc. or one of 1 company grouped under it. 8 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 16, 2026.
Keep track of what changes. Save the AbelZeta Inc. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to AbelZeta Inc..
- Shanghai AbelZeta Ltd.18 studies →Subsidiary
Something wrong?
- AbelZeta Inc.6 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 24 of 24.
- A Phase I Trial of A-CAR032 in Participants With mCRPCRecruitingNCT07344311Phase 1
Sponsor listed in the registry: Shanghai AbelZeta Ltd.
- Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell TherapyNot yet recruitingNCT07875413Phase 2
- C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Lupus Nephritis Refractory to Standard TherapyNot yet recruitingNCT07729826Phase 2
- C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard TherapyNot yet recruitingNCT07825389Phase 1/2
- C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard TherapyNot yet recruitingNCT07854483Phase 1
- An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Metastatic Squamous Cell Lung CancerRecruitingNCT07444281Phase 1
Sponsor listed in the registry: Shanghai AbelZeta Ltd.
- A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell LymphomaRecruitingNCT05800977Phase 1/2
Sponsor listed in the registry: Shanghai AbelZeta Ltd.
- A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT05521802Phase 1/2
Sponsor listed in the registry: Shanghai AbelZeta Ltd.
- A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)Active, not recruitingNCT06590246Phase 1/2
Sponsor listed in the registry: Shanghai AbelZeta Ltd.
- C-CAR168 CAR T Cell Therapy for Refractory Autoimmune DiseaseWithdrawnNCT06935474Phase 1/2
- C-TIL051 in Non-Small Cell Lung CancerTerminatedNCT05676749Phase 1
- Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells for the Treatment of Knee OsteoarthritisCompletedNCT04208646Phase 2
Sponsor listed in the registry: Shanghai AbelZeta Ltd.
- AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular CarcinomaStatus unknownNCT03971747Phase 1
Sponsor listed in the registry: Shanghai AbelZeta Ltd.
- A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL SubjectsCompletedNCT02976857Phase 1
Sponsor listed in the registry: Shanghai AbelZeta Ltd.
- Clinical Trial to Compare ReJoinTM to Sodium Hyaluronate Injection for Knee Osteoarthritis Cartilage DefectsStatus unknownNCT02855073Phase 2
Sponsor listed in the registry: Shanghai AbelZeta Ltd.
- Clinical Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Knee OsteoarthritisCompletedNCT02641860Phase 1
Sponsor listed in the registry: Shanghai AbelZeta Ltd.
- A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHLStatus unknownNCT03299738Phase 1
Sponsor listed in the registry: Shanghai AbelZeta Ltd.
- Clinical Trial of Autologous Adipose Tissue-Derived Mesenchymal Progenitor Cells (MPCs) Therapy for Knee OsteoarthritisCompletedNCT02162693Phase 2
Sponsor listed in the registry: Shanghai AbelZeta Ltd.
- Study of Safety and Efficacy of C-CAR011 in B-NHL PatientsStatus unknownNCT03154775Phase 1
Sponsor listed in the registry: Shanghai AbelZeta Ltd.
- Autologous Immune Cell Therapy in Combination With LHRH-a in Patients With mCRPCStatus unknownNCT03085966Phase 1/2
Sponsor listed in the registry: Shanghai AbelZeta Ltd.
- A Phase I Study Evaluating Safety and Efficacy of C-CAR011 Treatment in Adult Subjects With r/r CD19+B-ALLStatus unknownNCT03018093Phase 1
Sponsor listed in the registry: Shanghai AbelZeta Ltd.
- Autologous Adipose Tissue Derived Mesenchymal Stem Cells Therapy for Patients With Knee OsteoarthritisCompletedNCT01809769Phase 1/2
Sponsor listed in the registry: Shanghai AbelZeta Ltd.
- The Study of Surgery,Chemotherapy and Autologous T Cells-Based Immunotherapy for Advanced Gastric Cancer.Status unknownNCT02704299Early Phase 1
Sponsor listed in the registry: Shanghai AbelZeta Ltd.
- Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE TherapyCompletedNCT01828762Not applicable
Sponsor listed in the registry: Shanghai AbelZeta Ltd.